Quantcast

Latest schizophrenia Stories

2014-03-06 08:30:23

-- Significantly Higher Drug Exposure Achieved with Continued Tolerability -- SEATTLE, March 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the...

2014-03-04 23:25:04

The global market for drugs used to treat mental disorders was valued at $70.1 billion in 2012 and is estimated to have declined slightly to nearly $69 billion in 2013. BCC Research projects the market to grow to nearly $77.1 billion by 2018, and register a five-year compound annual growth rate of 2.3% from 2013 to 2018. Wellesley, Mass., (PRWEB) March 04, 2014 According to a new technical market research report Drugs for Treating Mental Disorders: Technologies and Global Markets, from...

2014-03-03 08:31:55

ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults MOUNTAIN VIEW, Calif., March 3, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE(®) (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute...

2014-03-03 08:30:51

NEW YORK, March 3, 2014 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease....

2014-02-26 16:28:49

NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34(th) Annual Healthcare Conference on March 3, 2014 at 2:50 p.m. Eastern Time in Boston, MA. Dr. Mates will provide a corporate overview and business update. The live and archived webcast of the company presentation can be accessed under "Events and Presentations" in the...

2014-02-24 09:12:45

Columbia University Medical Center Potential target for treating autism, schizophrenia, and other brain disorders NEW YORK, NY (February 23, 2014) — Columbia University Medical Center (CUMC) researchers have determined that a small region of the hippocampus known as CA2 is essential for social memory, the ability of an animal to recognize another of the same species. A better grasp of the function of CA2 could prove useful in understanding and treating disorders characterized by...

Understanding Autism And Schizophrenia
2014-02-24 08:21:53

Mathilde Weirsøe, Aarhus University In a study to be published in Psychological Science, researchers from Aarhus University and the University of Copenhagen demonstrate that brain cells in what is called the mirror system help people make sense of the actions they see other people perform in everyday life. Using magnetic stimulation to temporarily disrupt normal processing of the areas of the human brain involved in the production of actions of human participants, it is demonstrated...

2014-02-21 23:03:33

Drug Allgedly Linked to Breast Enlargement in Males DALLAS (PRWEB) February 21, 2014 The national plaintiffs’ law firm of Baron and Budd announces that it is now handling lawsuits relative to the drug Risperdal. Risperdal is prescribed to treat children, adolescents and adults with schizophrenia. Baron and Budd lawyers are working with males who allegedly suffered breast enlargement after taking the drug. Risperdal, manufactured by Johnson & Johnson, was first approved by the Food...

2014-02-19 08:32:36

LONDON, Feb. 19, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: EpiCast Report: Schizophrenia - Epidemiology Forecast to 2022 EpiCast Report: Schizophrenia - Epidemiology Forecast to 2022 Summary Schizophrenia is a chronic, severe, and disabling group of psychotic disorders characterized by fundamental disturbances of thinking such as hallucinations, delusions, disorganized communication, and reduced motivation. Schizophrenia affects men and...

2014-02-19 08:30:37

-- PDE10 Inhibitor Administered to Patients with Huntington's Disease -- SEATTLE, Feb. 19, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related